Mecamylamine transdermal - AGI Therapeutics

Drug Profile

Mecamylamine transdermal - AGI Therapeutics

Alternative Names: AGI-004

Latest Information Update: 15 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AGI Therapeutics
  • Developer Horizon Pharma
  • Class Eye disorder therapies; Norbornanes; Small molecules
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diarrhoea

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-II for Diarrhoea (Chemotherapy-induced) in Europe (Transdermal)
  • 15 Sep 2015 No recent reports on development identified - Phase-II for Diarrhoea (functional diarrhoea) in USA (Transdermal)
  • 13 Mar 2009 Efficacy and adverse events data from a Phase-II trial in Chemotherapy-induced diarrhoea released by AGI Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top